1. Home
  2. |Insights
  3. |ASBCA's FY16 Report – a Look at the Numbers

ASBCA's FY16 Report – a Look at the Numbers

Client Alert | less than 1 min read | 02.06.17

The Armed Services Board of Contract Appeals published its FY16 Report of Transactions and Proceedings, which provides statistics regarding the adjudication of appeals between contractors and the Army, Navy, Air Force, Corps of Engineers, DLA, DCMA, CIA, NASA, other Defense agencies, and the Washington Metropolitan Area Transit Authority. According to this year's report, appellants prevailed in 57 percent of the appeals decided on the merits (up from 53 percent in FY15). As usual, the Board had a high success rate in resolving matters via alternative dispute resolution (ADR), successfully resolving an impressive 93 percent of ADRs concluded in FY16 – including binding arbitration, non-binding mediation, and ADR of undocketed appeals.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights